Early Phase 1 N=6 Investigation of Female Reproductive Hormone Dynamics During Adolescence
Menstruation Disturbances
Primary: Ovulation in Cycle 2 — 3; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=4 Relationship Between the Menstrual Cycle and Heart Disease in Women
Coronary Heart Disease
Primary: Total to HDL Cholesterol Ratio — 0.146; 0.148; -0.89 Total to HDL Cholesterol Ratio
Phase 3 N=45 Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Number of Menses During the Six Month Study Period. — .42; .42; .75; .25 Number of menstrual cycles per month
N/A N=1,000 Duphaston in Cycle Regularization: A Post-marketing, Prospective, Multicenter, Observational Study
Irregular Menstrual Cycle
Primary: Percentage of Patients Reporting a Regular Cycle — 96.7 percentage of participants
Phase 4 N=34 Estrogen Variability and Irritability During the Menopause Transition
Menopause · Irritable Mood
Primary: Mean IDAS Ill Temper Scale Score Over Time — 6.19; 6.02 score on a scale — p=0.09
N/A N=104 Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding
Heavy Menstrual Bleeding
Primary: Hot Flush Frequency Total Score (HFRS) Change — 9.3; 8.8; 12.7 score on a scale
N/A N=999 Treatment Regimen in Menstrual Cycle Regularization and Persistence in Routine Clinical Practice in Russia, Ukraine, Kazakhstan and Uzbekistan
Irregular Menstrual Cycle
Primary: Number of Patients Received Dydrogesterone Therapy Cycles (by Cycle Number) — 1; 4; 269; 66 participants
Phase 4 N=51 Continuous Versus Cyclical OCP Use in PCOS
Polycystic Ovary Syndrome
Primary: Change in Biochemical Hyperandrogenism From Baseline to 1 Month Post Yasmin Initiation — -15.38; -8.54 ng/dl
N/A N=38 Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale
N/A N=25 Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Polycystic Ovary Syndrome · Hyperandrogenism
Primary: Change in Progesterone Sensitivity Index Before and After Metformin Treatment. — -4.12; -4.29 % change in LH pulses/day 7 P4 level
N/A N=79 Evaluation of Ovarian Morphology and Function in Overweight Women During Weight Loss
Weight Loss · Anovulation · Amenorrhea
Primary: Change From Baseline Ovulatory/Menstrual Function — 12; 18 Participants
N/A N=11 The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle
Ovulation (Follicular Rupture Yes/no) · Menstrual Cycles (Total Length, Bleeding Days) · Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)
Primary: Menstrual Cycle Length — 28.5; 27.2 Days
N/A N=15 Development of an Advisory System for Glycemic Control During the Menstrual Cycle in Patient With Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: High Blood Glucose Index (HBGI) — 6.87; 8.05; 7.92; 9.00 index score — p=0.023
Phase 2 N=265 A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women
Hemostasis · Oral Contraceptive
Primary: Change From Baseline to End of Month 6 in Prothrombin Fragment 1+2 Levels — 169.53; 157.99; 592.29 pmol/L — p=0.958
Phase 4 N=64 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism
Polycystic Ovary Syndrome
Primary: Biochemical Assessment of Hyperandrogenism — 0.7; 0.7 Index — p=<.0001
Phase 4 N=353 Chronic Pain Risk Associated With Menstrual Period Pain
Cystitis, Interstitial · Dysmenorrhea · Migraine Disorders
Primary: Change in Participant Bladder Pain Sensitivity From Baseline. — 38.2; 37.0; 41.2; 47.9 score on a scale — p=.02
N/A N=68 Study to Evaluate the Efficacy of Elix's Cycle Balance and Its Impact on PMS and Menstrual Symptoms
PMS · Menstrual Pain
Primary: Relief From Premenstrual Cramps [Time Frame: Baseline to 3 Months] — 4.41; 3.48; 3.12; 2.72 score on a scale — p=<0.001
N/A N=64 Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Primary: Follicle-stimulating Hormone — 5.01; 5.86; 6.38 milli international units per milliliter — p=0.88
Phase 2 N=95 A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain
Dysmenorrhea
Primary: Mean Change in Average Severity for Abdominal/Pelvic Pain — -0.45; -0.19 units on a scale
Phase 4 N=58 Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users
Bleeding · Implants · Breakthrough Bleeding
Primary: Total Number of Days Without Bleeding or Spotting — 17.5; 16.7 days
Phase 3 N=105 Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding
Menorrhagia
Primary: Number of Participants With Successful Treatment of Heavy Menstrual Bleeding — 81; 83 Participants
Phase 2 N=36 Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
Prostate · Cancer · Hormonal Cycling
Primary: Response — 22; 4; 3 participants
N/A N=8 Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women
Healthy
Primary: To Determine the Impact of GABA-A Receptor Agonists (Benzodiazepines, Allopregnanolone) and Other GABA-modulating Agents (Fluoxetine) on Cortical GABA Levels by…
N/A N=71 Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation
Metrorrhagia
Primary: Mean Number of Bleeding or Spotting Days — 16; 28 days
Phase 2 N=109 A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches
Migraine
Primary: Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the Treatment Period — 48.1; 48.9 percentage of participants — p=0.954
N/A N=60 Dysregulation of FSH in Obesity: Functional and Statistical Analysis
Obesity · Fertility
Primary: Difference Between Peak Inhibin B — 100.8; 38.8 picograms/mL
Phase 4 N=67 Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)
Premenstrual Dysphoric Disorder
Primary: Pre-Post Change in Premenstrual Symptom Severity — 1.93; 1.73; 1.64 units on a scale
Phase 3 N=1,166 Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles
Contraception
Primary: Number of Days With Bleeding Including Spotting — 41; 61; 66 days — p=<0.0001
Phase 4 N=28 Copper IUD Treatment Observation Study
Menorrhagia
Primary: Mean Days of Bleeding and Spotting, Spotting Only and Bleeding Only for the 84 Day Treatment Cycles and Last 28 Day Post-treatment Cycle — 29.2; 23.0; 9.3; 9.6 days…
N/A N=79 Tracking IUD Bleeding Experiences: An Evaluation of Bleeding Profiles in New Intrauterine Device Users
Intrauterine Devices, Copper · Metrorrhagia · Menstruation
Primary: Evaluate Changes in Bleeding Duration Among Women Initiating the Copper T380 IUD During the 90 Days Prior to Initiation Compared to Two 90 Periods After IUD Insertion…